Treatment-related adverse events
| System organ class (N = 35) . | All grades . | Grade 1, n (%) . | Grade 2, n (%) . | Grade 3, n (%) . | Grade 4, n (%) . |
|---|---|---|---|---|---|
| Lymphocyte count decreased | 9 (26) | 3 (9) | 3 (9) | 2 (6) | 1 (3) |
| Anemia | 8 (23) | 8 (23) | 0 | 0 | 0 |
| Diarrhea | 7 (20) | 5 (14) | 2 (6) | 0 | 0 |
| Fatigue | 7 (20) | 5 (14) | 1 (3) | 1 (3) | |
| Headache | 6 (17) | 5 (14) | 1 (3) | 0 | 0 |
| Upper respiratory infection | 6 (17) | 0 | 6 (17) | 0 | 0 |
| Back pain | 5 (14) | 4 (11) | 1 (3) | 0 | 0 |
| Nausea | 5 (14) | 5 (14) | 0 | 0 | 0 |
| Constipation | 4 (11) | 4 (11) | 0 | 0 | 0 |
| Vomiting | 4 (11) | 3 (9) | 1 (3) | 0 | 0 |
| Anorexia | 3 (9) | 3 (9) | 0 | 0 | 0 |
| Cough | 3 (9) | 2 (6) | 1 (3) | 0 | 0 |
| Insomnia | 3 (9) | 1 (3) | 2 (3) | 0 | 0 |
| Pain | 3 (9) | 3 (9) | 0 | 0 | 0 |
| Lung infection | 2 (6) | 0 | 0 | 2 (6) | 0 |
| System organ class (N = 35) . | All grades . | Grade 1, n (%) . | Grade 2, n (%) . | Grade 3, n (%) . | Grade 4, n (%) . |
|---|---|---|---|---|---|
| Lymphocyte count decreased | 9 (26) | 3 (9) | 3 (9) | 2 (6) | 1 (3) |
| Anemia | 8 (23) | 8 (23) | 0 | 0 | 0 |
| Diarrhea | 7 (20) | 5 (14) | 2 (6) | 0 | 0 |
| Fatigue | 7 (20) | 5 (14) | 1 (3) | 1 (3) | |
| Headache | 6 (17) | 5 (14) | 1 (3) | 0 | 0 |
| Upper respiratory infection | 6 (17) | 0 | 6 (17) | 0 | 0 |
| Back pain | 5 (14) | 4 (11) | 1 (3) | 0 | 0 |
| Nausea | 5 (14) | 5 (14) | 0 | 0 | 0 |
| Constipation | 4 (11) | 4 (11) | 0 | 0 | 0 |
| Vomiting | 4 (11) | 3 (9) | 1 (3) | 0 | 0 |
| Anorexia | 3 (9) | 3 (9) | 0 | 0 | 0 |
| Cough | 3 (9) | 2 (6) | 1 (3) | 0 | 0 |
| Insomnia | 3 (9) | 1 (3) | 2 (3) | 0 | 0 |
| Pain | 3 (9) | 3 (9) | 0 | 0 | 0 |
| Lung infection | 2 (6) | 0 | 0 | 2 (6) | 0 |
All patients who received at least 1 dose of isatuximab were included. Shown are the most common adverse events of any grade.